Trastuzumab

Generic Name
Trastuzumab
Brand Names
Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ontruzant, Perjeta-Herceptin, Phesgo, Trazimera, Herwenda, Ogivri, Zercepac, Tuznue
Drug Type
Biotech
Chemical Formula
-
CAS Number
180288-69-1
Unique Ingredient Identifier
P188ANX8CK
Background

Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth factor receptor (HER)-2+ metastatic bre...

Indication

For the adjuvant treatment of HER2-overexpressing breast cancer, trastuzumab is indicated in several clinical settings: as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; as part of a treatment regimen with docetaxel and carboplatin; or as monotherapy following multi-modality anthracycline-based th...

Associated Conditions
Breast Cancer, Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Adenocarcinoma of the Stomach, Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage I Breast Cancer
Associated Therapies
-
Clinical Trials
Related News

Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer

First Posted Date
2020-12-24
Last Posted Date
2020-12-24
Lead Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Target Recruit Count
80
Registration Number
NCT04683445
Locations
🇨🇳

Sun Yat Sen Memorial Hospital，Sun Yat sen University, Guangzhou, Guangdong, China

Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction

First Posted Date
2020-12-23
Last Posted Date
2024-03-15
Lead Sponsor
Population Health Research Institute
Target Recruit Count
130
Registration Number
NCT04680442
Locations
🇧🇷

Clínica de Pesquisa e Centro de Estudos em Oncologia Ginecológica e Mamária Ltda, São Paulo, Brazil

🇧🇷

Irmandade Da Santa Casa De Misericórdia De Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil

🇧🇷

Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil

and more 5 locations

A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction

First Posted Date
2020-12-10
Last Posted Date
2024-11-06
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
42
Registration Number
NCT04661150
Locations
🇨🇳

Nanfang Hospital, Southern Medical University, Guangzhou, China

🇨🇳

First Hospital of China Medical University; Surgery, Shenyang City, China

🇨🇳

Tianjin Medical University Cancer Institute & Hospital, Tianjin, China

and more 6 locations

Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis

First Posted Date
2020-11-20
Last Posted Date
2020-11-20
Lead Sponsor
Shandong Cancer Hospital and Institute
Target Recruit Count
100
Registration Number
NCT04639271
Locations
🇨🇳

Zhiyong Yu, Jinan, Shandong, China

Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.

First Posted Date
2020-11-16
Last Posted Date
2024-04-19
Lead Sponsor
Qilu Pharmaceutical Co., Ltd.
Target Recruit Count
517
Registration Number
NCT04629846
Locations
🇨🇳

Fudan University Cancer Hospital, Shanghai, Shanghai, China

🇨🇳

Tianjin Medical University Cancer Institution & Hospital, Tianjin, Tianjin, China

Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC

First Posted Date
2020-10-30
Last Posted Date
2020-12-16
Lead Sponsor
Shandong Cancer Hospital and Institute
Target Recruit Count
200
Registration Number
NCT04609540

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

First Posted Date
2020-10-19
Last Posted Date
2024-05-03
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
39
Registration Number
NCT04588545
Locations
🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

🇺🇸

Northwestern University, Evanston, Illinois, United States

The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

First Posted Date
2020-10-19
Last Posted Date
2023-10-03
Lead Sponsor
Fondazione per la Medicina Personalizzata
Target Recruit Count
400
Registration Number
NCT04591431
Locations
🇮🇹

I.R.S.T. Srl Irccs, Meldola, Italy

🇮🇹

Ospedale Classificato Sacro Cuore - Don Calabria, Negrar, Italy

🇮🇹

I.R.C.C.S. Istituto Oncologico Veneto, Padova, Italy

and more 34 locations

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

First Posted Date
2020-10-08
Last Posted Date
2024-11-13
Lead Sponsor
Seagen Inc.
Target Recruit Count
217
Registration Number
NCT04579380
Locations
🇺🇸

HealthPartners Institute, Saint Louis Park, Minnesota, United States

🇺🇸

Texas Oncology, P.A. - Dallas, Dallas, Texas, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

and more 63 locations

CRAFT: the NCT-PMO-1602 Phase II Trial

First Posted Date
2020-09-16
Last Posted Date
2024-12-11
Lead Sponsor
German Cancer Research Center
Target Recruit Count
175
Registration Number
NCT04551521
Locations
🇩🇪

Charité - Universitätsmedizin Berlin, Berlin, Germany

🇩🇪

Nationales Centrum für Tumorerkrankungen (NCT), Heidelberg, Germany

🇩🇪

Universitätsklinikum Freiburg, Freiburg, Germany

and more 5 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy